Cargando…
Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells
Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immu...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cognizant Communication Corporation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751222/ https://www.ncbi.nlm.nih.gov/pubmed/32560747 http://dx.doi.org/10.3727/096504020X15925659763817 |
_version_ | 1783625624488771584 |
---|---|
author | Li, Dong Sun, Fei-fan Wang, Dan Wang, Tao Peng, Jing-jing Feng, Jian-Qiong Li, Hua Wang, Chao Zhou, Dai-jun Luo, Hong Fu, Zeng-qiang Zhang, Tao |
author_facet | Li, Dong Sun, Fei-fan Wang, Dan Wang, Tao Peng, Jing-jing Feng, Jian-Qiong Li, Hua Wang, Chao Zhou, Dai-jun Luo, Hong Fu, Zeng-qiang Zhang, Tao |
author_sort | Li, Dong |
collection | PubMed |
description | Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug resistance and suppressed the migration, invasion, colony formation, and tumorigenesis in sorafenib-resistant hepatoma cells in vitro and in vivo. Mechanistic investigations indicated that loss of microRNA-1 (miR-1), a tumor-suppressive microRNA, contributed to the PD-L1 upregulation in sorafenib-resistant hepatoma cells, and PD-L1 was a direct regulatory target of miR-1. Further study revealed that an oncogenic transcriptional factor, nuclear factor E2-related factor 2 (NRF-2), was induced in sorafenib-resistant hepatoma cells and inhibited expression of miR-1 in vitro. From molecular mechanism insight back to the functional verification, we eventually demonstrated that miR-1 executed its tumor-suppressive effects on drug resistance and other malignant properties in sorafenib-resistant hepatoma cells partially by PD-L1 inhibition in vitro and in vivo. In conclusion, our data suggested that a NRF-2/miR-1/PD-L1 regulatory axis contributed to the development and maintenance of drug resistance and other tumorigenic properties in sorafenib-resistant hepatoma cells and provided a potential therapeutic target for overcoming sorafenib resistance in HCC. |
format | Online Article Text |
id | pubmed-7751222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cognizant Communication Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-77512222021-02-16 Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells Li, Dong Sun, Fei-fan Wang, Dan Wang, Tao Peng, Jing-jing Feng, Jian-Qiong Li, Hua Wang, Chao Zhou, Dai-jun Luo, Hong Fu, Zeng-qiang Zhang, Tao Oncol Res Article Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug resistance and suppressed the migration, invasion, colony formation, and tumorigenesis in sorafenib-resistant hepatoma cells in vitro and in vivo. Mechanistic investigations indicated that loss of microRNA-1 (miR-1), a tumor-suppressive microRNA, contributed to the PD-L1 upregulation in sorafenib-resistant hepatoma cells, and PD-L1 was a direct regulatory target of miR-1. Further study revealed that an oncogenic transcriptional factor, nuclear factor E2-related factor 2 (NRF-2), was induced in sorafenib-resistant hepatoma cells and inhibited expression of miR-1 in vitro. From molecular mechanism insight back to the functional verification, we eventually demonstrated that miR-1 executed its tumor-suppressive effects on drug resistance and other malignant properties in sorafenib-resistant hepatoma cells partially by PD-L1 inhibition in vitro and in vivo. In conclusion, our data suggested that a NRF-2/miR-1/PD-L1 regulatory axis contributed to the development and maintenance of drug resistance and other tumorigenic properties in sorafenib-resistant hepatoma cells and provided a potential therapeutic target for overcoming sorafenib resistance in HCC. Cognizant Communication Corporation 2020-12-10 /pmc/articles/PMC7751222/ /pubmed/32560747 http://dx.doi.org/10.3727/096504020X15925659763817 Text en Copyright © 2020 Cognizant, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under a Creative Commons Attribution-NonCommercial NoDerivatives 4.0 International License. |
spellingShingle | Article Li, Dong Sun, Fei-fan Wang, Dan Wang, Tao Peng, Jing-jing Feng, Jian-Qiong Li, Hua Wang, Chao Zhou, Dai-jun Luo, Hong Fu, Zeng-qiang Zhang, Tao Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells |
title | Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells |
title_full | Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells |
title_fullStr | Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells |
title_full_unstemmed | Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells |
title_short | Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells |
title_sort | programmed death ligand-1 (pd-l1) regulated by nrf-2/microrna-1 regulatory axis enhances drug resistance and promotes tumorigenic properties in sorafenib-resistant hepatoma cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751222/ https://www.ncbi.nlm.nih.gov/pubmed/32560747 http://dx.doi.org/10.3727/096504020X15925659763817 |
work_keys_str_mv | AT lidong programmeddeathligand1pdl1regulatedbynrf2microrna1regulatoryaxisenhancesdrugresistanceandpromotestumorigenicpropertiesinsorafenibresistanthepatomacells AT sunfeifan programmeddeathligand1pdl1regulatedbynrf2microrna1regulatoryaxisenhancesdrugresistanceandpromotestumorigenicpropertiesinsorafenibresistanthepatomacells AT wangdan programmeddeathligand1pdl1regulatedbynrf2microrna1regulatoryaxisenhancesdrugresistanceandpromotestumorigenicpropertiesinsorafenibresistanthepatomacells AT wangtao programmeddeathligand1pdl1regulatedbynrf2microrna1regulatoryaxisenhancesdrugresistanceandpromotestumorigenicpropertiesinsorafenibresistanthepatomacells AT pengjingjing programmeddeathligand1pdl1regulatedbynrf2microrna1regulatoryaxisenhancesdrugresistanceandpromotestumorigenicpropertiesinsorafenibresistanthepatomacells AT fengjianqiong programmeddeathligand1pdl1regulatedbynrf2microrna1regulatoryaxisenhancesdrugresistanceandpromotestumorigenicpropertiesinsorafenibresistanthepatomacells AT lihua programmeddeathligand1pdl1regulatedbynrf2microrna1regulatoryaxisenhancesdrugresistanceandpromotestumorigenicpropertiesinsorafenibresistanthepatomacells AT wangchao programmeddeathligand1pdl1regulatedbynrf2microrna1regulatoryaxisenhancesdrugresistanceandpromotestumorigenicpropertiesinsorafenibresistanthepatomacells AT zhoudaijun programmeddeathligand1pdl1regulatedbynrf2microrna1regulatoryaxisenhancesdrugresistanceandpromotestumorigenicpropertiesinsorafenibresistanthepatomacells AT luohong programmeddeathligand1pdl1regulatedbynrf2microrna1regulatoryaxisenhancesdrugresistanceandpromotestumorigenicpropertiesinsorafenibresistanthepatomacells AT fuzengqiang programmeddeathligand1pdl1regulatedbynrf2microrna1regulatoryaxisenhancesdrugresistanceandpromotestumorigenicpropertiesinsorafenibresistanthepatomacells AT zhangtao programmeddeathligand1pdl1regulatedbynrf2microrna1regulatoryaxisenhancesdrugresistanceandpromotestumorigenicpropertiesinsorafenibresistanthepatomacells |